| Literature DB >> 16545139 |
Subramani Durai Babu1, Venkataraman Jayanthi, Niranjali Devaraj, Celso A Reis, Halagowder Devaraj.
Abstract
BACKGROUND: Helicobacter pylori (H. pylori) causes gastritis and intestinal metaplasia (IM) that may evolve to gastric carcinoma. The objective of this study was to compare the profile of mucins in the progressive stages of H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. We used a panel of monoclonal antibodies with well-defined specificities of MUC2, MUC5AC and MUC6 to characterize the expression pattern of mucins by immunohistochemistry.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16545139 PMCID: PMC1479362 DOI: 10.1186/1476-4598-5-10
Source DB: PubMed Journal: Mol Cancer ISSN: 1476-4598 Impact factor: 27.401
Figure 1Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC2 staining of normal gastric mucosa (Original magnification ×100). b. MUC5AC staining of normal gastric mucosa (Original magnification ×100). c. MUC6 staining of normal gastric mucosa (Original magnification ×100). d. MUC2 staining of Atrophic gastritis (Original magnification ×100). e. MUC5AC staining of Atrophic gastritis (Original magnification ×100). f. MUC6 staining of Atrophic gastritis (Original magnification ×100). g. MUC2 staining of Intestinal metaplasia (Original magnification ×100). h. MUC5AC staining of Intestinal metaplasia (Original magnification ×100).
Figure 3Expression pattern of mucins (MUC2, MUC5AC and MUC6) in . a. MUC2 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. b. MUC5AC expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium. c. MUC6 expression in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium.
Expression of mucins (MUC2, MUCSAC and MUC6) in H. pylori infected pre-neoplastic and neoplastic human gastric epithelium
| H. pylori | |||||||||||||||||
| Normal (n = 7) | 7 | - | n = 7 (100%) | - | - | - | - | - | - | - | n = 2 (28.6%) | n = 5 (71.4%) | - | - | - | 1 (14.3%) | 6 (85.7%) |
| Atrophic gastritis (n = 26) | - | 26 | n = 22 (84.6%) | n = 4 (15.4%) | - | - | - | - | - | 1 (38%) | 13 (50%) | 12 (46.2%) | - | - | 1 (3.8%) | 15 (57.7%) | 10 (38.5%) |
| Intestinal metaplasia (n = 21) | - | 21 | - | - | n = 9 (42.9%) | n = 12 (57.1%)** | - | - | 1 (4.8%) | 16 (76.2%)** | 4 (19%) | - | - | 5 (23.8%) | 14 (66.7%)** | 2 (9.5%) | - |
| Dysplasia (n = 17) | - | 17 | - | n = 5 (29.4%) | n = 11 (64.7%) | n = 1 (5.9%) | - | - | 3 (17.6%) | 10 (58.8%) | 4 (23.5%) | - | - | 3 (17.6%) | 11 (64.7%) | 3 (17.3%) | - |
| Carcinoma (n = 36) | - | 36 | - | 22 (61.1%) | 14 (38.9%) | - | - | - | 28 (77.8%) | 8 (22.2%) | - | - | 12 (33.3%) | 17 (47.2%) | 7 (19.4%) | - | - |
N – negative - (> 5%) negative
P – positive + (5–25%) few positive cells
n – No. of cases ++ (25–50%) well-defined area
+++ (50–75%) extensive area stained
++++ (75–100%) most of the cells stained
**p < 0.00, *p < 0.05 (Significant difference in expression)
Figure 2Immunohistochemical staining of MUC2, MUC5AC and MUC6 mucins in . a. MUC6 staining of Intestinal metaplasia (Original magnification ×100). b. MUC2 staining of dysplasia (Original magnification ×100). c. MUC5AC staining of dysplasia (Original magnification ×100). d. MUC6 staining of dysplasia (Original magnification ×100). e. MUC2 staining of carcinoma (Original magnification ×100). f. MUC5AC staining of carcinoma (Original magnification ×100). g. MUC6 staining of carcinoma (Original magnification ×100).
Specificities, origins and dilutions of the monoclonal antibodies.
| PMH1 | MUC2 | Reis | Undiluted |
| CLH2 | MUC5AC | Reis | 1:2 |
| CLH5 | MUC6 | Reis | 1:2 |